← Back to Search

Penicillin Antibiotic

Antibiotics for Neonatal Infections (NANO Trial)

Phase 4
Recruiting
Research Sponsored by Michael Morowitz
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
We will enroll newborn infants with gestational age of 23-30 weeks 6 days infants at participating study sites will be eligible.
Be younger than 18 years old
Must not have
Infants with ongoing hemodynamic instability requiring vasopressors or fluid boluses at time of randomization
Infants born to mothers with previous infant with GBS disease/infection
Timeline
Screening 3 weeks
Treatment Varies
Follow Up weekly stool samples will be collected for the first 8 weeks of life and then monthly through death or discharge from the subject's birth hospital , assessed up to 50 weeks.
Awards & highlights

Summary

This trial is testing whether it's better to give antibiotics to extremely low birthweight babies right away or wait to see if they get an infection.

Who is the study for?
The trial is for newborns born at 23-30 weeks gestation, who are clinically stable without signs of infection or severe respiratory issues. It excludes those with major congenital anomalies, infants expected not to survive beyond 72 hours, and babies whose mothers had infections like GBS disease or chorioamnionitis.
What is being tested?
This study tests whether giving antibiotics (Ampicillin and Gentamycin) to extremely low birthweight infants in their first week affects the rates of sepsis, necrotizing enterocolitis, or death compared to a placebo (Normal saline).
What are the potential side effects?
Potential side effects may include reactions to antibiotics such as rash or diarrhea. Long-term use might lead to antibiotic resistance or affect the development of the baby's gut microbiome.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My newborn is between 23 and 30 weeks old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My infant needs medicine or fluids to maintain blood pressure.
Select...
My previous child had a GBS infection.
Select...
I am a mother and I am under 18 years old.
Select...
My baby was born by C-section without labor induction or signs of maternal infection.
Select...
My infant needs a breathing machine and extra oxygen.
Select...
My infant has received antibiotics before being chosen for the study.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~weekly stool samples will be collected for the first 8 weeks of life and then monthly through death or discharge from the subject's birth hospital , assessed up to 50 weeks.
This trial's timeline: 3 weeks for screening, Varies for treatment, and weekly stool samples will be collected for the first 8 weeks of life and then monthly through death or discharge from the subject's birth hospital , assessed up to 50 weeks. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Composite incidence of NEC, LOS, or death
Secondary study objectives
Death
LOS
NEC
Other study objectives
Microbial diversity within infant fecal samples

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Empiric antibioticsActive Control2 Interventions
Infants will receive standard antibiotic coverage of ampicillin and gentamycin at site approved dosing guidelines while completing an evaluation for early-onset neonatal sepsis.
Group II: PlaceboPlacebo Group1 Intervention
Infants will receive a volume matched placebo of normal saline while completing an evaluation for early-onset neonatal sepsis.

Find a Location

Who is running the clinical trial?

Michael MorowitzLead Sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH
2,014 Previous Clinical Trials
2,696,032 Total Patients Enrolled
5 Trials studying Neonatal Sepsis
5,865 Patients Enrolled for Neonatal Sepsis

Media Library

Ampicillin (Penicillin Antibiotic) Clinical Trial Eligibility Overview. Trial Name: NCT03997266 — Phase 4
Neonatal Sepsis Research Study Groups: Empiric antibiotics, Placebo
Neonatal Sepsis Clinical Trial 2023: Ampicillin Highlights & Side Effects. Trial Name: NCT03997266 — Phase 4
Ampicillin (Penicillin Antibiotic) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03997266 — Phase 4
~147 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top